Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | Improving the QoL of patients with hemophilia with inhibitors

Mehran Karimi, MD, Hematology Research Center Shiraz University of Medical Sciences, Shiraz, Iran, comments on the quality of life (QoL) of patients with hemophilia with inhibitors, discussing management strategies for these patients. Prof. Karimi explains that patients with inhibitors have an increased risk of morbidity and mortality, as well as significantly decreased QoL. Different therapies can be given depending on the patient’s inhibitor levels, including recombinant FVIII, bypassing agents, and emicizumab. It is also important to improve the social environment of patients with inhibitors to further improve their QoL. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.